In a recent discussion at SLAS Europe 2026, insights were shared regarding the innovative work at the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), particularly in the realm of proximity-inducing drugs.
The ITMP focuses on bridging academic research with industrial applications, emphasizing the integration of drug screening and medical data science. This approach aims to enhance drug discovery by combining traditional laboratory work with data-driven methodologies, ultimately to improve patient treatment outcomes. The institute is dedicated to advancing technologies that can be effectively utilized in the pharmaceutical industry.
Proximity-inducing drugs, or proxy drugs, represent a novel class of small molecules that differ from conventional drugs by modulating protein interactions within cells rather than merely inhibiting protein functions. These drugs create ternary complexes involving a target protein, an E3 ligase, and the small molecule itself, facilitating processes like ubiquitination that lead to protein degradation. This innovative mechanism allows for targeting previously considered "undruggable" proteins, such as transcription factors.
However, challenges remain in the development of these drugs, particularly concerning their size and bioavailability. The complexity of bifunctional proximity-inducing drugs, which require high molecular weights, poses difficulties for oral delivery and effective brain penetration. Additionally, achieving cooperative binding in ternary complexes is still an area that lacks comprehensive understanding, necessitating collaborative research efforts to establish clear guidelines for drug development.
Ultimately, the success of these innovative therapies hinges on collaboration between academia and industry, fostering an interdisciplinary environment that combines diverse expertise to tackle the intricate challenges of drug development. This collaborative spirit is vital for advancing the science and ensuring that new therapeutic options can effectively serve patients.